NCT01359254

Cord Blood Transplantation for Patients With Cancer

Combined Transplantation of Unmanipulated Haploidentical and a SingleCord Blood Unit for Patients With Hematologic Malignancies

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: University of Chicago · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to assess the rate of engraftment with combined haploidentical-cord blood transplantation in patients with pre-existing donor specific antibodies and in those with active disease.

Detailed description

Primary Objective \- To assess the rate of engraftment with combined haploidentical-cord blood transplantation in patients with pre-existing donor specific anti-HLA antibodies and in those with active disease Secondary Objectives * To determine the long term fate of the haplo transplant and the cord blood transplant in this setting. * To describe the incidence and severity of acute and chronic GVHD.

Conditions

• Hematological Disease

Interventions

Type	Name	Description
DRUG	Melphalan	Melphalan is given daily for 2 days, overlapping with the completion of fludarabine.
DRUG	Fludarabine	Fludarabine is given through the vein daily for 5 days.
DRUG	Antithymocyte Globulin (ATG)	ATG is given every other day for 4 days.
DRUG	Busulfan	Busulfan is given daily for 4 days.
DRUG	Total Body Irradiation (TBI)	TBI is given twice on the last day.

Timeline

• Start date: 2010-04-01
• Primary completion: 2011-09-01
• Completion: 2012-06-01
• First posted: 2011-05-24
• Last updated: 2015-04-30
• Results posted: 2015-04-30

Locations

1 site across 1 country: United States